“Roflumilast (Daliresp®) to reduce acute pulmonary events in fibrotic sarcoidosis: a multi-center, double blind, placebo controlled, randomized clinical trial”, Sarcoidosis Vasc Diffuse Lung Dis, vol. 38, no. 3, p. e2021035, Sep. 2021, doi: 10.36141/svdld.v38i3.11684.